Health Catalyst, Inc. (NASDAQ:HCAT) Given Average Recommendation of “Hold” by Brokerages

Shares of Health Catalyst, Inc. (NASDAQ:HCAT) have been assigned a consensus rating of “Hold” from the fourteen research firms that are currently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, eight have given a hold recommendation and five have issued a buy recommendation on the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $4.3636.

HCAT has been the subject of a number of research analyst reports. William Blair reiterated an “outperform” rating on shares of Health Catalyst in a research report on Tuesday, November 11th. BTIG Research restated a “neutral” rating on shares of Health Catalyst in a report on Friday, September 5th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Health Catalyst in a report on Monday, December 22nd. KeyCorp reduced their price objective on Health Catalyst from $5.00 to $4.00 and set an “overweight” rating for the company in a research report on Wednesday, October 8th. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating and set a $4.00 price target on shares of Health Catalyst in a research note on Tuesday, October 7th.

Health Catalyst Stock Performance

Shares of HCAT stock opened at $2.52 on Tuesday. The company has a market capitalization of $178.24 million, a price-to-earnings ratio of -1.58 and a beta of 1.72. Health Catalyst has a 1-year low of $2.02 and a 1-year high of $7.65. The company has a current ratio of 1.88, a quick ratio of 1.88 and a debt-to-equity ratio of 0.46. The stock’s fifty day simple moving average is $2.70 and its 200-day simple moving average is $3.15.

Health Catalyst (NASDAQ:HCAT) last announced its quarterly earnings data on Monday, November 10th. The company reported $0.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.05 by $0.01. The firm had revenue of $76.32 million during the quarter, compared to the consensus estimate of $75.05 million. Health Catalyst had a negative return on equity of 6.67% and a negative net margin of 34.05%. On average, sell-side analysts predict that Health Catalyst will post -0.33 earnings per share for the current fiscal year.

Insider Activity at Health Catalyst

In related news, General Counsel Benjamin Landry sold 27,425 shares of the firm’s stock in a transaction that occurred on Friday, December 5th. The shares were sold at an average price of $2.64, for a total transaction of $72,402.00. Following the transaction, the general counsel owned 100,000 shares of the company’s stock, valued at approximately $264,000. This trade represents a 21.52% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Julie Larson-Green sold 47,997 shares of the stock in a transaction on Thursday, December 4th. The stock was sold at an average price of $2.67, for a total transaction of $128,151.99. Following the transaction, the director owned 73,573 shares in the company, valued at approximately $196,439.91. This trade represents a 39.48% decrease in their position. The disclosure for this sale is available in the SEC filing. 2.60% of the stock is currently owned by company insiders.

Institutional Trading of Health Catalyst

A number of institutional investors and hedge funds have recently made changes to their positions in HCAT. First Light Asset Management LLC increased its holdings in shares of Health Catalyst by 9.9% during the 3rd quarter. First Light Asset Management LLC now owns 13,436,220 shares of the company’s stock valued at $38,293,000 after acquiring an additional 1,206,039 shares during the last quarter. Vanguard Group Inc. boosted its position in Health Catalyst by 2.9% during the third quarter. Vanguard Group Inc. now owns 4,295,691 shares of the company’s stock worth $12,243,000 after purchasing an additional 119,117 shares during the period. Geode Capital Management LLC grew its holdings in Health Catalyst by 11.4% during the second quarter. Geode Capital Management LLC now owns 1,662,455 shares of the company’s stock valued at $6,269,000 after purchasing an additional 169,580 shares during the last quarter. Millennium Management LLC grew its holdings in Health Catalyst by 2,513.3% during the third quarter. Millennium Management LLC now owns 1,589,536 shares of the company’s stock valued at $4,530,000 after purchasing an additional 1,528,710 shares during the last quarter. Finally, Acadian Asset Management LLC raised its position in shares of Health Catalyst by 25.1% in the second quarter. Acadian Asset Management LLC now owns 1,163,785 shares of the company’s stock valued at $4,385,000 after purchasing an additional 233,556 shares during the period. Institutional investors and hedge funds own 85.00% of the company’s stock.

Health Catalyst Company Profile

Health Catalyst (NASDAQ: HCAT) is a healthcare data and analytics technology company founded in 2008 and headquartered in Salt Lake City, Utah. The company went public in 2019 and has since focused on delivering a unified data platform that helps healthcare organizations aggregate and analyze clinical, financial and operational information.

The core of Health Catalyst’s offering is the Data Operating System (DOS), a modular data management platform that integrates disparate data sources—from electronic health records to claims and patient-generated data—into a single analytics environment.